Syntara Limited's latest marketcap:
As of 07/16/2025, Syntara Limited's market capitalization has reached $54.09 M. According to our data, Syntara Limited is the 29288th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 54.09 M |
| Revenue (ttm) | 5.32 M |
| Net Income (ttm) | -7,768,240.7 |
| Shares Out | 1.63 B |
| EPS (ttm) | -0.01 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 07/28/2025 |
Syntara Limited's yearly market capitalization.
| Date | Market Cap(A$) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/16/2025 | A$82.92 M | $54.09 M | -36.93% | 29288 |
| 12/31/2024 | A$126.33 M | $78.16 M | 660.1% | 24919 |
| 12/29/2023 | A$16.62 M | $11.31 M | -62.11% | 36566 |
| 12/30/2022 | A$43.86 M | $29.88 M | -30.29% | 30244 |
| 12/31/2021 | A$62.92 M | $45.64 M | 70.33% | 28102 |
| 12/31/2020 | A$36.94 M | $28.42 M | -41.51% | 27806 |
| 12/31/2019 | A$63.15 M | $44.3 M | -39.56% | 22555 |
| 12/31/2018 | A$104.49 M | $73.64 M | 28.16% | 18895 |
| 12/29/2017 | A$81.53 M | $63.66 M | -8.64% | 20307 |
| 12/30/2016 | A$89.24 M | $64.26 M | -21.83% | 18113 |
Company Profile
About Syntara Limited
Syntara Limited is a clinical-stage drug development company specializing in treatments for blood-related cancers and other serious conditions. Headquartered in Frenchs Forest, Australia, the company was incorporated in 1998 and rebranded from Pharmaxis Ltd in December 2023.
Key Product Pipeline
- SNT-5505 – Currently in Phase 2 trials for myelofibrosis, myelodysplastic syndrome, hepatocellular carcinoma, pancreatic cancer, and scar prevention.
- SNT-4728 – A Phase 2 candidate targeting neurodegenerative diseases, including isolated rapid eye movement sleep behavior disorder (IRBD) and Parkinson’s disease.
- SNT-5382 – A selective lysyl oxidase-like 2 inhibitor in Phase 1 trials for chronic fibrosis.
- SNT-8370 – A therapeutic candidate focused on treating inflammation.
With a strong emphasis on innovative therapies, Syntara Limited continues to advance its clinical programs to address unmet medical needs.
Frequently Asked Questions
-
What is Syntara Limited's (ASX-SNT) current market cap?As of 07/16/2025, Syntara Limited (including the parent company, if applicable) has an estimated market capitalization of $54.09 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Syntara Limited (ASX-SNT) rank globally by market cap?Syntara Limited global market capitalization ranking is approximately 29288 as of 07/16/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.